These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 19242289)

  • 1. Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls.
    Daughton JM; Kratochvil CJ
    J Am Acad Child Adolesc Psychiatry; 2009 Mar; 48(3):240-248. PubMed ID: 19242289
    [No Abstract]   [Full Text] [Related]  

  • 2. Update on drugs for hyperactivity in childhood.
    Drug Ther Bull; 2007 May; 45(5):37-40. PubMed ID: 17536494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of new compounds available in Australia for the treatment of attention-deficit hyperactivity disorder.
    Hazell P
    Australas Psychiatry; 2004 Dec; 12(4):369-75. PubMed ID: 15715810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second opinions improve ADHD prescribing in a medicaid-insured community population.
    Thompson JN; Varley CK; McClellan J; Hilt R; Lee T; Kwan AC; Lee T; Trupin E
    J Am Acad Child Adolesc Psychiatry; 2009 Jul; 48(7):740-748. PubMed ID: 19465882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological management of attention-deficit hyperactivity disorder.
    Reeves G; Schweitzer J
    Expert Opin Pharmacother; 2004 Jun; 5(6):1313-20. PubMed ID: 15163276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis.
    Peterson K; McDonagh MS; Fu R
    Psychopharmacology (Berl); 2008 Mar; 197(1):1-11. PubMed ID: 18026719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atomoxetine and nonresponders to stimulants.
    Velcea G; Winsberg BG
    Am J Psychiatry; 2004 Sep; 161(9):1718-9. PubMed ID: 15337674
    [No Abstract]   [Full Text] [Related]  

  • 8. Non-stimulant trials of adult ADHD.
    Adler LA
    CNS Spectr; 2007 Apr; 12(4 Suppl 6):11-3. PubMed ID: 17717871
    [No Abstract]   [Full Text] [Related]  

  • 9. Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder.
    Biederman J; Spencer T; Wilens T
    Int J Neuropsychopharmacol; 2004 Mar; 7(1):77-97. PubMed ID: 14733627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults.
    Santosh PJ; Sattar S; Canagaratnam M
    CNS Drugs; 2011 Sep; 25(9):737-63. PubMed ID: 21870887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety of non-stimulant agents for the treatment of attention-deficit hyperactivity disorder.
    Himpel S; Banaschewski T; Heise CA; Rothenberger A
    Expert Opin Drug Saf; 2005 Mar; 4(2):311-21. PubMed ID: 15794722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The practice and problem of therapeutic agents for AD/HD].
    Tanaka H; Miyajima T
    No To Hattatsu; 2010 May; 42(3):213-6. PubMed ID: 23858580
    [No Abstract]   [Full Text] [Related]  

  • 13. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom.
    Cottrell S; Tilden D; Robinson P; Bae J; Arellano J; Edgell E; Aristides M; Boye KS
    Value Health; 2008; 11(3):376-88. PubMed ID: 18489664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD?
    Niederhofer H
    Psychiatr Danub; 2009 Sep; 21(3):330. PubMed ID: 19794351
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
    Stuhec M; Munda B; Svab V; Locatelli I
    J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Close up on atomoxetine: a nonstimulant choice for treating ADHD.
    Allen C; Pitcock J
    Adv Nurse Pract; 2006 Mar; 14(3):39-40, 42-3, 78. PubMed ID: 16548127
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008.
    Kornfield R; Watson S; Higashi AS; Conti RM; Dusetzina SB; Garfield CF; Dorsey ER; Huskamp HA; Alexander GC
    Psychiatr Serv; 2013 Apr; 64(4):339-46. PubMed ID: 23318985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of pharmacotherapy for attention deficit hyperactivity disorder on risk of seizures in pediatric patients as assessed in an insurance claims database.
    McAfee AT; Holdridge KC; Johannes CB; Hornbuckle K; Walker AM
    Curr Drug Saf; 2008 May; 3(2):123-31. PubMed ID: 18690990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of adult ADHD and comorbid disorders.
    Young JL
    CNS Spectr; 2006 Oct; 11(10 Suppl 11):10-2. PubMed ID: 17712918
    [No Abstract]   [Full Text] [Related]  

  • 20. New developments in the treatment of ADHD.
    Biederman J; Arnsten AF; Faraone SV; Doyle AE; Spencer TJ; Wilens TE; Weiss MD; Safren SA; Culpepper L
    J Clin Psychiatry; 2006 Jan; 67(1):148-59. PubMed ID: 16426101
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.